This article reports a study conducted on rheumatoid arthritis (RA) patients for assessing the efficacy of biologic response modulator (BRM) drugs where routinely used anti-rheumatoid arthritis treatment strategies have failed. The study shows promising results, however similar studies, and clinical trials are warranted. Study Background Around 1% Indian population is estimated to have affected with rheumatoid arthritis (RA). Therapy including disease modifying anti-rheumatoid arthritis drugs (DMARDs) should be included in the early stage, and a delay of 9 months impacts the clinical outcome adversely.
The most frequently used DMARD is methotrexate (MTX) is associated with limited efficacy. Whereas the introduction of biologic response modulator (BRMs) for the treatment of RA brings a significant improvement in the patient condition. However, use of BRMs is limited due to higher costs.…
